Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNovo Nordisk Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 4 | $5.35 | $6.21 | $5.75 |
| Q2 2026 | 3 | $4.73 | $5.34 | $5.03 |
| Q3 2026 | 3 | $4.53 | $5.19 | $4.89 |
| Q4 2026 | 2 | $3.41 | $4.93 | $4.42 |
| Q1 2027 | 1 | $5.91 | $6.69 | $6.38 |
| Q2 2027 | 1 | $5.34 | $6.04 | $5.76 |
| Q3 2027 | 1 | $5.08 | $5.75 | $5.49 |
| Q4 2027 | 1 | $4.78 | $5.41 | $5.16 |
Novo Nordisk Earnings Date And Information
Novo Nordisk last posted its earnings results on Wednesday, November 4th, 2026. The company reported $0.89 earnings per share for the quarter, topping analysts' consensus estimates of $0.731 by $0.159. The company had revenue of 78.68 B for the quarter and had revenue of 309.06 B for the year. Novo Nordisk has generated $23 earnings per share over the last year ($23.03 diluted earnings per share) and currently has a price-to-earnings ratio of 10.63. Novo Nordisk has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Novo Nordisk Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/04/2026 | Q3 2026 | $0.73 | $3.74 | 3.01 | $74.13 B | $78.68 B |
| 08/04/2026 | Q2 2026 | N/A | $4.74 | N/A | $71.20 B | $78.49 B |
| 05/06/2026 | Q1 2026 | $0.87 | $10.93 | 10.06 | $70.60 B | $96.82 B |
| 02/03/2026 | Q4 2025 | $0.90 | $6.06 | 5.16 | $77.12 B | $79.14 B |
| 11/05/2025 | Q3 2025 | $0.77 | $4.50 | 3.73 | $76.03 B | $74.98 B |
| 08/06/2025 | Q2 2025 | $0.93 | $5.96 | 5.03 | $75.85 B | $76.86 B |
| 05/07/2025 | Q1 2025 | $0.92 | $6.54 | 5.62 | $80.62 B | $78.09 B |
| 02/05/2025 | Q4 2024 | $0.88 | $6.34 | 5.46 | $79.59 B | $85.68 B |
| 09/30/2024 | Q3 2024 | N/A | $6.13 | N/A | $70.57 B | $71.31 B |
| 06/30/2024 | Q2 2024 | N/A | $4.50 | N/A | $69.28 B | $68.06 B |
| 03/31/2024 | Q1 2024 | N/A | $5.70 | N/A | $63.38 B | $65.35 B |
| 12/31/2023 | Q4 2023 | N/A | $4.92 | N/A | $62.03 B | $65.86 B |
| 09/30/2023 | Q3 2023 | N/A | $5.02 | N/A | $57.80 B | $58.73 B |
| 06/30/2023 | Q2 2023 | N/A | $4.33 | N/A | $56.03 B | $54.30 B |
| 03/31/2023 | Q1 2023 | N/A | $4.40 | N/A | $52.46 B | $53.37 B |
| 12/31/2022 | Q4 2022 | N/A | $3.02 | N/A | $47.28 B | $48.09 B |
| 09/30/2022 | Q3 2022 | N/A | $3.17 | N/A | $44.89 B | $45.57 B |
| 06/30/2022 | Q2 2022 | N/A | $2.93 | N/A | $40.76 B | $41.27 B |
| 03/31/2022 | Q1 2022 | N/A | $3.11 | N/A | $38.77 B | $42.03 B |
| 12/31/2021 | Q4 2021 | N/A | $2.38 | N/A | $37.79 B | $38.33 B |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Novo Nordisk Earnings: FAQ's
In the previous quarter, Novo Nordisk (:NVO) reported $0.89 earnings per share (EPS) to beat the analysts' consensus estimate of $0.731 by $0.159.
The conference call for Novo Nordisk's latest earnings report can be listened to online.
The conference call transcript for Novo Nordisk's latest earnings report can be read online.
Novo Nordisk (:NVO) has a recorded annual revenue of $309.06 B.
Novo Nordisk (:NVO) has a recorded net income of $102.43 B.Novo Nordisk has generated $23.06 earnings per share over the last four quarters.
Novo Nordisk (:NVO) has a price-to-earnings ratio of 10.63 and price/earnings-to-growth ratio is 1.14.